ReMederi
ReMederi is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at ReMederi.
ReMederi is a company.
Key people at ReMederi.
Key people at ReMederi.
ReMederi is a Brazilian health company focused on medical cannabis, enabling legal access to cannabis-based products, services, and education to improve quality of life for patients.[1][2] It serves patients with medical prescriptions, healthcare professionals, and businesses by simplifying importation processes under ANVISA regulations (recognized since 2015 and updated via RDC nº660/2022), providing certified GMP products, scientific education, and streamlined support from consultation to delivery.[1][2] The company addresses challenges in prescribing, accessing, and investing in medical cannabis, emphasizing care, science-backed knowledge, safety, and ease of use, which drives its growth in Brazil's emerging market.[1][2]
ReMederi was founded in 2018 by Fabrizio Postiglione, stemming from his personal pain experience that highlighted unmet needs in medical cannabis access.[1] This personal motivation led to the creation of a global health company tailored to Brazil's regulatory landscape, where ANVISA first allowed cannabis product importation in 2015.[1][2] Early traction built on simplifying complex processes for patients and doctors, evolving into a comprehensive platform with certified products, education for prescribers, and global networking for businesses.[1][2]
ReMederi rides the global medical cannabis wave in Brazil, capitalizing on ANVISA's 2015 legalization of imports and 2022 updates that expand access amid rising demand for alternative therapies.[2] Timing aligns with growing scientific validation of cannabis for various conditions, market maturation, and health tech trends emphasizing patient-centric digital platforms for regulated substances.[1][2] It influences the ecosystem by bridging gaps in education and logistics, empowering prescribers, supporting patients, and fostering business investment in cannabis—accelerating adoption in a developing market.[1][2]
ReMederi is poised for expansion as Brazil's medical cannabis market matures, potentially scaling education tools, product portfolios, and B2B networking amid regulatory evolution and rising prescriptions.[1][2] Trends like digital health integration, international partnerships, and evidence-based advocacy will shape its path, enhancing influence in Latin America's cannabis ecosystem. This positions it to transform quality-of-life access, building directly on its founder-driven mission.[1][2]
